Recruitment for this study has closed. This means new people cannot sign-up for the study, but we will continue to collect data from study participants until March 2025.
We provide the information below for study participants.
What is HypoPAST?
HypoPAST (Hypoglycaemia Prevention, Awareness of Symptoms and Treatment) is a new online program which aims to help adults with type 1 diabetes worry less about hypos. It may also help them learn skills to help prevent and manage severe hypos. This study will test the HypoPAST program to find out how well it achieves these aims.
If we learn that HypoPAST is beneficial to adults with type 1 diabetes, we will be able to offer it to more people with diabetes in the future.
What do HypoPAST study participants need to do?
-
- Use the HypoPAST program. Half of the people in the study will be able to use the program straight away (HypoPAST now group). The other half of the people will be able to use the program after 6 months (HypoPAST wait-list group). There are 8 modules, you can choose to do them all, or just the ones that interest you. We recommend doing 1 or 2 modules per week. You can do each module at your own pace, we recommend setting aside about an hour per module. If you find any modules particularly useful, you can print materials or go back to them anytime during the 6 months.
-
- Answer questions about you, your diabetes, your hypos and how they affect you, in an:
-
-
- online survey (3 times during the study, about 45 minutes per survey)
- app (2 times per day, for 2 weeks, at 2 times during the study; about 10 mins per day).
- This will help us to learn how well the HypoPAST program works.
-
-
- Some people will be invited to take part in a telephone interview (about 30-45 mins). This will help us to know how well the HypoPAST program suits people with type 1 diabetes.
We show the steps in this infographic
Log-in to the HypoPAST program (HypoPAST now participants only) here
Read the Study Information
Contact us hypopast@deakin.edu.au
HypoPAST is proudly funded by the Medical Research Future Fund (MRFF) Targeted Translation Research Accelerator (TTRA), with in-kind support from our partners: Diabetes Australia, Diabetes Victoria, Australian Diabetes Educators Association, Australian Diabetes Society, Deakin University, La Trobe University, Monash University, Newcastle University, and uMotif.
This study has ethics approval from Deakin University (2023-132).
